Episode Details

Back to Episodes
A Glaucoma Eye Drop Designed to Protect the Optic Nerve Is Already in Phase II Trials

A Glaucoma Eye Drop Designed to Protect the Optic Nerve Is Already in Phase II Trials

Published 2 months, 1 week ago
Description

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/a-glaucoma-eye-drop-designed-to-protect-the-optic-nerve-is-already-in-phase-ii-trials

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

A Glaucoma Eye Drop Designed to Protect the Optic Nerve Is Already in Phase II Trials Status reviewed: September 4, 2026 Introduction Glaucoma treatment has one major limitation: lowering intraocular pressure protects the eye indirectly, but it does not directly repair or support retinal ganglion cells. Some patients continue to lose retinal nerve fibers and visual field despite apparently acceptable pressure control. G01 eye drops are designed to address that gap. The active ingredient is described as recombinant human nerve growth factor variant 2, or rhNGF-V2. The drug is being tested in a randomized Phase II trial in people with progressing primary open-angle glaucoma whose intraocular pressure is already controlled. The central question is whether a protein placed on the eye’s surface can reach the retina and optic nerve in a sufficient amount to: keep stressed retinal ganglion cells alive; restore function to damaged but living cells; stabilize retinal nerve fiber and ganglion-cell layers; or, more ambitiously, regenerate damaged optic-nerve connections. The short answer is: > G01 is biologically plausible as a neuroprotective and possibly neuroenhancing treatment. Genuine optic-nerve regeneration is much less established. The largest unresolved problem is whether enough of the drug reaches the posterior eye after topical dosing. The evidence is promising but uneven. Much of the strongest evidence comes from animal models and a small human case series. A previous randomized trial of conventional recombinant human nerve growth factor was safe but did not show statistically significant short-term improvement. G01 may be more potent because it is a modified molecule, but that remains unproven in humans. --- The Current Phase II G01 Trial The study is registered as NCT07777861, titled: > “A Randomized, Double-Masked, Placebo-Controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of G01 Eye Drops in the Treatment of Optic Nerve Injury Associated With Open-Angle Glaucoma.” It is being sponsored by Qingdao WanMing BioCell Pharmaceutics Co., Ltd. in China. The trial began enrolling on March 18, 2026. The registry lists an estimated 90 participants, with primary completion expected on October 1, 2027, and overall study completion on December 1, 2027. No results had been posted as of September 4, 2026. G01 trial record () Trial design For the full table, please open this article on visualfieldtest.com. The public registry lists two active concentrations and a placebo. Its summary formatting is not entirely consistent about the number of “groups,” but the intervention listing clearly describes two active dose arms plus a matched placebo arm. The precise allocation ratio is not stated in the accessible public record. G01 trial record () Who can enter the study? The trial is designed for people with active, measurable glaucoma progression, not simply people with an abnormal optic nerve. Key inclusion criteria include: Primary open-angle glaucoma in one or both eyes. Progression in the study eye demonstrated by Guided Progression Analysis of visual-field tests. Visual-field mean deviation between −3 and −16 decibels. Best-corrected visual acuity of at least 0.3 in decimal notation. Intraocular pressure between 10 and 21 millimeters of mercury, with pressure considered stable b

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us